Get started
Author

Tressie Herrmann

Observed names: Herrmann, Tressie, T. Herrmann
ORCID: 0000-0001-8077-6068
Observed ORCID: 0000-0001-8077-6068
OpenAlex ID: A5041524810
Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma
2021 · Tressie Herrmann, Cécile Mione, et al. · Oncology · 27
Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study
2021 · Tressie Herrmann, Angeline Ginzac, et al. · Cancer Medicine · 25
PDF
Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group
2023 · M. Guerin, C. Miran, et al. · Frontiers in Oncology · 20
PDF
Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab
2023 · Nathan El-ghazzi, Xavier Durando, et al. · OncoTargets and Therapy · 18
PDF
Predictive and Prognostic Factors in Epithelial Ovarian Cancer: A Review
2025 · Alexia Giro, Tressie Herrmann, et al. · Indian Journal of Gynecologic Oncology · 8
PDF
Intrinsic validity of molecular marker(s) detection on tissue tumor DNA to predict efficacy of 177Lutetium-PSMA-617 ([177Lu]Lu-PSMA-617) treatment for castration-resistant metastatic prostate cancer (PSMA-PRED): study protocol of a prospective multicentre clinical trial
2026 · Judith Passildas, Marie-Céleste Ferreira, et al. · BMC Cancer
Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study
2026 · Karim Amrane, Luca Campedel, et al. · Cancer Immunology Immunotherapy
980 Histological, Clinical and Molecular Characterization of Brenner Tumors of the Ovary
2025 · Estelle Espinasse, Tressie Herrmann, et al. · Laboratory Investigation
Review of: "Personalized (tailored) treatment with antiresorptive drugs (bisphosphonates, denosumab) in patients with bone metastases from solid tumors – A “Pico” document by Rete Oncologica Piemonte-Valle D’Aosta Bone Metastatic Disease Study Group"
2023 · Tressie Herrmann
Mutation of Tp53 in a Patient with Aggressive Central Nervous System Solitary Fibrous Tumor/Hemangiopericytoma
2020 · de Bernardi, Axel, Bernadach, Maureen, et al. · HAL
Works count: 11
Citation count: 98
H-index: 5
I10-index: 4
Year
Topic
Type